

Jae-Gook Shin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5182381/publications.pdf>

Version: 2024-02-01

149
papers

4,948
citations

101496

36
h-index

110317

64
g-index

151
all docs

151
docs citations

151
times ranked

5779
citing authors

#	ARTICLE	IF	CITATIONS
1	Ongoing Initiatives in Bringing the Preemptive Panelâ€”Based Pharmacogenetic Testing to Clinical Decisions in Vietnam. <i>IFMBE Proceedings</i> , 2022, , 553-567.	0.2	0
2	The frequency of the known mitochondrial variants associated with drug-induced toxicity in a Korean population. <i>BMC Medical Genomics</i> , 2022, 15, 3.	0.7	2
3	Development of population pharmacokinetics model of isoniazid in Indonesian patients with tuberculosis. <i>International Journal of Infectious Diseases</i> , 2022, 117, 8-14.	1.5	12
4	Physiologically-based pharmacokinetic modeling of nafamostat to support dose selection for treatment of pediatric patients with COVID-19. <i>Translational and Clinical Pharmacology</i> , 2022, 30, 24.	0.3	3
5	Characterization of Clofazimine as a Potential Substrate of Drug Transporter. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0215821.	1.4	2
6	Center for Personalized Precision Medicine for Tuberculosis: Smart Research and Development Workstation. <i>Healthcare Informatics Research</i> , 2022, 28, 176-180.	1.0	2
7	Semi-Automated Therapeutic Drug Monitoring as a Pillar toward Personalized Medicine for Tuberculosis Management. <i>Pharmaceutics</i> , 2022, 14, 990.	2.0	8
8	Identification and functional study of genetic polymorphisms in cyclic nucleotide phosphodiesterase 3A (PDE3A). <i>Annals of Human Genetics</i> , 2021, 85, 80-91.	0.3	3
9	Pharmacokinetics and Pharmacodynamics of Tegoprazan Coadministered With Amoxicillin and Clarithromycin in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 913-922.	1.0	10
10	Associations between HLA-A, -B, and -C alleles and iodinated contrast mediaâ€”induced hypersensitivity in Koreans. <i>Translational and Clinical Pharmacology</i> , 2021, 29, 107.	0.3	1
11	Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1567-1578.	1.0	14
12	Paraâ€”aminosalicylic acid significantly reduced tenofovir exposure in human subjects; mismatched findings from in vitro to in vivo translational research. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	3
13	A 10-gene biosignature of tuberculosis treatment monitoring and treatment outcome prediction. <i>Tuberculosis</i> , 2021, 131, 102138.	0.8	10
14	Identification and functional characterization of CYP4V2 genetic variants exhibiting decreased activity of lauric acid metabolism. <i>Annals of Human Genetics</i> , 2020, 84, 400-411.	0.3	4
15	Inhibition of 20-hydroxyeicosatetraenoic acid (20-HETE) glucuronidation by non-steroidal anti-inflammatory drugs in human liver microsomes and recombinant UDP-glucuronosyltransferase enzymes. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2020, 153, 102055.	1.0	4
16	Survey of physicians' views on the clinical implementation of pharmacogenomics-based personalized therapy. <i>Translational and Clinical Pharmacology</i> , 2020, 28, 34.	0.3	14
17	Antiepileptic drug-induced severe cutaneous adverse reactions and <i>HLA</i> alleles: A report of five cases with lymphocyte activation test. <i>Translational and Clinical Pharmacology</i> , 2019, 27, 64.	0.3	5
18	NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in Indonesian population. <i>Pharmacogenomics</i> , 2019, 20, 1303-1311.	0.6	15

#	ARTICLE	IF	CITATIONS
19	Physiologically Based Pharmacokinetic Modeling Approach to Predict Drug-Drug Interactions With Ethionamide Involving Impact of Genetic Polymorphism on FMO3. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 880-889.	1.0	7
20	Rifampin Induces Expression of P-glycoprotein on the THP1 Cell-Derived Macrophages, Causing Decrease Intramacrophage Concentration of Prothionamide. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 3106-3111.	1.6	4
21	Pharmacokinetics of Single Doses of BI 425809 in Healthy Chinese and Japanese Subjects: A Randomized Study. <i>Clinical Therapeutics</i> , 2019, 41, 961-971.	1.1	5
22	A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males. <i>BioDrugs</i> , 2019, 33, 173-181.	2.2	14
23	Influences of cytochrome b5 expression and its genetic variant on the activity of CYP2C9, CYP2C19 and CYP3A4. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 201-208.	1.1	8
24	Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Subjects. <i>BioMed Research International</i> , 2019, 2019, 1-6.	0.9	5
25	Effect of rifampin on enantioselective disposition and anti-hypertensive effect of benidipine. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 737-745.	1.1	3
26	What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision Dosing. <i>AAPS Journal</i> , 2019, 21, 17.	2.2	29
27	Identification of novel CYP4F2 genetic variants exhibiting decreased catalytic activity in the conversion of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE). <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2018, 131, 6-13.	1.0	20
28	Comprehensive Substrate Characterization of 22 Antituberculosis Drugs for Multiple Solute Carrier (SLC) Uptake Transporters <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	19
29	Development of a Physiologically Based Pharmacokinetic Model of Ethionamide in the Pediatric Population by Integrating Flavin-Containing Monooxygenase 3 Maturation Changes Over Time. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1347-1360.	1.0	6
30	THE EFFECTS OF CANDIDATE GENE IN PKPD PATHWAY ON ANTIPSYCHOTICS-INDUCED AMENORRHEA IN FEMALE SCHIZOPHRENIA PATIENTS. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-10-24.	0.0	0
31	Effects of cytochrome b5 expression and its genetic variant on the activity of CYP2C9, CYP2C19 and CYP3A4. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO3-14-15.	0.0	0
32	Role of 14-3-3 sigma in over-expression of P-gp by rifampin and paclitaxel stimulation through interaction with PXR. <i>Cellular Signalling</i> , 2017, 31, 124-134.	1.7	27
33	Evaluation of <i>para</i> -Aminosalicylic Acid as a Substrate of Multiple Solute Carrier Uptake Transporters and Possible Drug Interactions with Nonsteroidal Anti-inflammatory Drugs <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	18
34	Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 657-667.	1.0	17
35	Clinical Implementation of Pharmacogenomics for Personalized Precision Medicine: Barriers and Solutions. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2368-2379.	1.6	157
36	Functional characterization of a common CYP4F11 genetic variant and identification of functionally defective CYP4F11 variants in erythromycin metabolism and 20-HETE synthesis. <i>Archives of Biochemistry and Biophysics</i> , 2017, 620, 43-51.	1.4	12

#	ARTICLE	IF	CITATIONS
37	Expression of CYP4V2 in human THP1 macrophages and its transcriptional regulation by peroxisome proliferator-activated receptor gamma. <i>Toxicology and Applied Pharmacology</i> , 2017, 330, 100-106.	1.3	16
38	Comparative pharmacokinetics of a fixed-dose combination vs concomitant administration of telmisartan and S-amlodipine in healthy adult volunteers. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3543-3550.	2.0	7
39	Absolute bioavailability and pharmacokinetics of the angiotensin II receptor antagonist fimasartan in healthy subjects. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 576-580.	1.0	16
40	The Effect of Age on the Pharmacokinetics of Udenafil in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1372-1377.	1.0	1
41	The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to <i>CYP2C19</i> and <i>CYP3A5</i> genotypes. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 301-312.	1.1	21
42	Population Pharmacokinetic-Pharmacodynamic Analysis to Compare the Effect of Moxifloxacin on QT Interval Prolongation Between Healthy Korean and Japanese Subjects. <i>Clinical Therapeutics</i> , 2016, 38, 2610-2621.	1.1	8
43	Inhibitory Interaction Potential of 22 Antituberculosis Drugs on Organic Anion and Cation Transporters of the SLC22A Family. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6558-6567.	1.4	26
44	Pomegranate juice does not affect the disposition of simvastatin in healthy subjects. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2016, 41, 339-344.	0.6	14
45	Characterization of 22 Antituberculosis Drugs for Inhibitory Interaction Potential on Organic Anionic Transporter Polypeptide (OATP)-Mediated Uptake. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3096-3105.	1.4	21
46	Characterization of urinary metabolites as biomarkers of colistin-induced nephrotoxicity in rats by a liquid chromatography/mass spectrometry-based metabolomics approach. <i>Toxicology Letters</i> , 2016, 248, 52-60.	0.4	12
47	Contribution of GABRG2 Polymorphisms to Risk of Epilepsy and Febrile Seizure: a Multicenter Cohort Study and Meta-analysis. <i>Molecular Neurobiology</i> , 2016, 53, 5457-5467.	1.9	25
48	Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers. <i>Drug Metabolism and Pharmacokinetics</i> , 2016, 31, 107-116.	1.1	14
49	Low Serum Concentrations of Moxifloxacin, Prothionamide, and Cycloserine on Sputum Conversion in Multi-Drug Resistant TB. <i>Yonsei Medical Journal</i> , 2015, 56, 961.	0.9	19
50	Glucuronidation of fimasartan, a new angiotensin receptor antagonist, is mainly mediated by UGT1A3. <i>Xenobiotica</i> , 2015, 45, 10-18.	0.5	26
51	Analysis of genetic polymorphism and biochemical characterization of a functionally decreased variant in prostacyclin synthase gene (CYP8A1) in humans. <i>Archives of Biochemistry and Biophysics</i> , 2015, 569, 10-18.	1.4	19
52	Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 173-182.	1.1	37
53	Increased serum bile acid concentration following low-dose chronic administration of thioacetamide in rats, as evidenced by metabolomic analysis. <i>Toxicology and Applied Pharmacology</i> , 2015, 288, 213-222.	1.3	16
54	Casein Kinase 2 (CK2)-mediated Phosphorylation of Hsp90 α as a Novel Mechanism of Rifampin-induced MDR1 Expression. <i>Journal of Biological Chemistry</i> , 2015, 290, 17029-17040.	1.6	26

#	ARTICLE	IF	CITATIONS
55	Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography–electrospray ionization–tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 102, 9-16.	1.4	85
56	Genetic polymorphisms of CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in Vietnamese-Koreans. <i>Translational and Clinical Pharmacology</i> , 2014, 22, 70.	0.3	8
57	Enantioselective N-Demethylation and Hydroxylation of Sibutramine in Human Liver Microsomes and Recombinant Cytochrome P-450 Isoforms. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2014, 77, 1419-1430.	1.1	4
58	In Vitro Assay of Six UDP-Glucuronosyltransferase Isoforms in Human Liver Microsomes, Using Cocktails of Probe Substrates and Liquid Chromatography–Tandem Mass Spectrometry. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1803-1810.	1.7	39
59	Development of a Multiplex and Cost-Effective Genotype Test toward More Personalized Medicine for the Antiplatelet Drug Clopidogrel. <i>International Journal of Molecular Sciences</i> , 2014, 15, 7699-7710.	1.8	5
60	Resolution of a clinical AmpliChip CYP450 Test, no call: discovery and characterization of novel CYP2D6*1 haplotypes. <i>Pharmacogenomics</i> , 2014, 15, 1175-1184.	0.6	11
61	The effect of <i>Ginkgo biloba</i> extracts on the pharmacokinetics and pharmacodynamics of cilostazol and its active metabolites in healthy Korean subjects. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 821-830.	1.1	17
62	The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 850-857.	1.0	9
63	Multiple Cytochrome P450 Isoforms Are Involved in the Generation of a Pharmacologically Active Thiol Metabolite, whereas Paraoxonase 1 and Carboxylesterase 1 Catalyze the Formation of a Thiol Metabolite Isomer from Ticlopidine. <i>Drug Metabolism and Disposition</i> , 2014, 42, 141-152.	1.7	15
64	Genetic Variations in UDP-glucuronosyltransferase 2B15 in a Korean Population. <i>Drug Metabolism and Pharmacokinetics</i> , 2014, 29, 105-109.	1.1	1
65	The Pharmacogenomics of Cytochrome P450s: From Molecular to Clinical Application. , 2014, , 345-370.		1
66	The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (80% full dose) of peginterferon alfa-2a: a prospective randomized multicenter trial. <i>Hepatology International</i> , 2013, 7, 1000-1009.	1.9	2
67	Effects of clopidogrel and clarithromycin on the disposition of sibutramine and its active metabolites M1 and M2 in relation to CYP2B6 polymorphism. <i>Xenobiotica</i> , 2013, 43, 211-218.	0.5	5
68	CYP2C19 Poor Metabolizer Is Associated With Clinical Outcome of Clopidogrel Therapy in Acute Myocardial Infarction But Not Stable Angina. <i>Circulation: Cardiovascular Genetics</i> , 2013, 6, 514-521.	5.1	39
69	Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 244-253.	1.1	23
70	Reply to: Letter to the Editor – Impact of the CYP2C19*17 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Proton Pump Inhibitors. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 360-360.	1.0	0
71	The Tyrosine Kinase Inhibitor Nilotinib Selectively Inhibits CYP2C8 Activities in Human Liver Microsomes. <i>Drug Metabolism and Pharmacokinetics</i> , 2013, 28, 462-467.	1.1	10
72	Single Nucleotide Polymorphisms in SULT1A1 and SULT1A2 in a Korean Population. <i>Drug Metabolism and Pharmacokinetics</i> , 2013, 28, 372-377.	1.1	4

#	ARTICLE	IF	CITATIONS
73	Effect of HNF4 β genetic polymorphism G60D on the pharmacokinetics of CYP2D6 substrate tolterodine in healthy Korean individuals. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 175-179.	0.7	6
74	Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent. <i>PLoS ONE</i> , 2013, 8, e64114.	1.1	23
75	Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5. <i>Xenobiotica</i> , 2012, 42, 278-284.	0.5	27
76	LC-MS/MS for the simultaneous analysis of arachidonic acid and 32 related metabolites in human plasma: Basal plasma concentrations and aspirin-induced changes of eicosanoids. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 911, 113-121.	1.2	77
77	Effect of CYP2C19 Genetic Polymorphism on Pharmacokinetics and Pharmacodynamics and Pharmacodynamics of a New Proton Pump Inhibitor, Ilaprazole. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 976-984.	1.0	33
78	Rapid genotyping of the genetic variants of organic anion transporter 1 (OAT1), R50H, R23W, R454Q, and 505C>T, by pyrosequencing method. <i>Journal of Pharmaceutical Investigation</i> , 2012, 42, 71-76.	2.7	1
79	High-sensitivity liquid chromatography-tandem mass spectrometry for the simultaneous determination of five drugs and their cytochrome P450-specific probe metabolites in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 895-896, 56-64.	1.2	39
80	The Development of Automated Bed-allocation Expert System in Clinical Research Ward. <i>Journal of the Korean Society for Clinical Pharmacology and Therapeutics</i> , 2012, 20, 51.	0.1	0
81	Genetic polymorphisms in Na ⁺ -taurocholate co-transporting polypeptide (NTCP) and ileal apical sodium-dependent bile acid transporter (ASBT) and ethnic comparisons of functional variants of NTCP among Asian populations. <i>Xenobiotica</i> , 2011, 41, 501-510.	0.5	89
82	The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 820-828.	0.7	15
83	Simple and accurate quantitative analysis of ten antiepileptic drugs in human plasma by liquid chromatography/tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 56, 771-777.	1.4	70
84	Differential effect of genetic variants of Na ⁺ -taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. <i>Xenobiotica</i> , 2011, 41, 24-34.	0.5	74
85	Discovery of a Novel Allelic Variant of CYP2C8, CYP2C8*11, in Asian Populations and Its Clinical Effect on the Rosiglitazone Disposition In Vivo. <i>Drug Metabolism and Disposition</i> , 2011, 39, 711-716.	1.7	21
86	<i>In vitro</i> metabolism and transport of the new dipeptidyl peptidase 4 inhibitors, KR66222 and KR66223. <i>Xenobiotica</i> , 2011, 41, 445-455.	0.5	7
87	Identification of a null allele of cytochrome P450 3A7: CYP3A7 polymorphism in a Korean population. <i>Molecular Biology Reports</i> , 2010, 37, 213-217.	1.0	11
88	Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 126-131.	1.1	11
89	A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 213-221.	1.1	18
90	Itraconazole and Rifampin Alter Significantly the Disposition and Antihistamine Effect of Ebastine and Its Metabolites in Healthy Participants. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 195-204.	1.0	13

#	ARTICLE	IF	CITATIONS
91	Genetic Variations in UDP-glucuronosyltransferase 2B7 Gene (UGT2B7) in a Korean Population. <i>Drug Metabolism and Pharmacokinetics</i> , 2010, 25, 398-402.	1.1	15
92	Murrayafoline A attenuates the Wnt/ β -catenin pathway by promoting the degradation of intracellular β -catenin proteins. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 915-920.	1.0	35
93	Robust CYP2D6 genotype assay including copy number variation using multiplex single-base extension for Asian populations. <i>Clinica Chimica Acta</i> , 2010, 411, 2043-2048.	0.5	18
94	Identification of CYP19A1 single-nucleotide polymorphisms and their haplotype distributions in a Korean population. <i>Journal of Human Genetics</i> , 2010, 55, 189-193.	1.1	19
95	Identification of New CYP2C19 Variants Exhibiting Decreased Enzyme Activity in the Metabolism of S-Mephenytoin and Omeprazole. <i>Drug Metabolism and Disposition</i> , 2009, 37, 2262-2269.	1.7	38
96	Stimulation of protein kinase C δ suppresses colon cancer cell proliferation by down-regulation of β -catenin. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 2171-2180.	1.6	33
97	Isoreserpine promotes β -catenin degradation via Siah-1 up-regulation in HCT116 colon cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2009, 387, 444-449.	1.0	22
98	Discovery of Novel Functional Variants and Extensive Evaluation of CYP2D6 Genetic Polymorphisms in Koreans. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1464-1470.	1.7	64
99	Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 103-112.	0.7	48
100	Effect of Silymarin Supplement on the Pharmacokinetics of Rosuvastatin. <i>Pharmaceutical Research</i> , 2008, 25, 1807-1814.	1.7	57
101	Genetic polymorphism of hepatocyte nuclear factor-4 α influences human cytochrome P450 2D6 activity. <i>Hepatology</i> , 2008, 48, 635-645.	3.6	25
102	Simultaneous determination of udenafil and its active metabolite, DA-8164, in human plasma and urine using ultra-performance liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. <i>Biomedical Chromatography</i> , 2008, 22, 939-946.	0.8	13
103	Determination of two HMG-CoA reductase inhibitors, pravastatin and pitavastatin, in plasma samples using liquid chromatography-tandem mass spectrometry for pharmaceutical study. <i>Biomedical Chromatography</i> , 2008, 22, 131-135.	0.8	31
104	Determination of acetylsalicylic acid and its major metabolite, salicylic acid, in human plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study of Astrix [®] in Korean healthy volunteers. <i>Biomedical Chromatography</i> , 2008, 22, 590-595.	0.8	49
105	The monoterpenoids citral and geraniol are moderate inhibitors of CYP2B6 hydroxylase activity. <i>Chemico-Biological Interactions</i> , 2008, 174, 141-146.	1.7	31
106	Duplex pyrosequencing assay of the 388A>G and 521T>C SLCO1B1 polymorphisms in three Asian populations. <i>Clinica Chimica Acta</i> , 2008, 388, 68-72.	0.5	23
107	Duplex pyrosequencing of the TPMT β 3C and TPMT β 6 alleles in Korean and Vietnamese populations. <i>Clinica Chimica Acta</i> , 2008, 398, 82-85.	0.5	19
108	The Contributions of Cytochromes P450 3A4 and 3A5 to the Metabolism of the Phosphodiesterase Type 5 Inhibitors Sildenafil, Udenafil, and Vardenafil. <i>Drug Metabolism and Disposition</i> , 2008, 36, 986-990.	1.7	53

#	ARTICLE	IF	CITATIONS
109	Cytochrome P450 2B6 Catalyzes the Formation of Pharmacologically Active Sibutramine (N-[1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-N,N-dimethylamine) Metabolites in Human Liver Microsomes. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1679-1688.	1.7	40
110	Identification and Characterization of Potent CYP2B6 Inhibitors in Woohwangcheongsimwon Suspension, an Herbal Preparation Used in the Treatment and Prevention of Apoplexy in Korea and China. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1010-1015.	1.7	30
111	Identification and Functional Characterization of Genetic Variants of Human Organic Cation Transporters in a Korean Population. <i>Drug Metabolism and Disposition</i> , 2007, 35, 667-675.	1.7	93
112	The CYP3A4*18 Allele, the Most Frequent Coding Variant in Asian Populations, Does Not Significantly Affect the Midazolam Disposition in Heterozygous Individuals. <i>Drug Metabolism and Disposition</i> , 2007, 35, 2095-2101.	1.7	26
113	Identification and Functional Assessment of BCRP Polymorphisms in a Korean Population. <i>Drug Metabolism and Disposition</i> , 2007, 35, 623-632.	1.7	55
114	Comparisons of CYP2C19 Genetic Polymorphisms Between Korean and Vietnamese Populations. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 455-459.	1.0	38
115	Characterization of Benidipine and Its Enantiomers' Metabolism by Human Liver Cytochrome P450 Enzymes. <i>Drug Metabolism and Disposition</i> , 2007, 35, 1518-1524.	1.7	30
116	Development of the α -cocktail for High-throughput Evaluation of Five Human Cytochrome P450 Isoforms in vivo. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 531-540.	2.3	121
117	The effect of ABCG2 Δ V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 645-654.	1.1	51
118	Enzyme kinetic study of a new cardioprotective agent, KR-32570 using human liver microsomes and recombinant CYP isoforms. <i>Archives of Pharmacal Research</i> , 2007, 30, 469-474.	2.7	2
119	Characterization of the cytochrome P450 enzymes involved in the metabolism of a new cardioprotective agent KR-33028. <i>Toxicology Letters</i> , 2006, 166, 105-114.	0.4	10
120	In vitro metabolism of a new cardioprotective agent, KR-32570, in human liver microsomes. <i>Rapid Communications in Mass Spectrometry</i> , 2006, 20, 837-843.	0.7	7
121	Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 590-599.	2.3	52
122	Hexachlorophene Inhibits Wnt/ β -Catenin Pathway by Promoting Siah-Mediated β -Catenin Degradation. <i>Molecular Pharmacology</i> , 2006, 70, 960-966.	1.0	112
123	Characterization of Ebastine, Hydroxyebastine, and Carebastine Metabolism by Human Liver Microsomes and Expressed Cytochrome P450 Enzymes: Major Roles for CYP2J2 and CYP3A. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1793-1797.	1.7	75
124	Protein-kinase-C-mediated β -catenin phosphorylation negatively regulates the Wnt/ β -catenin pathway. <i>Journal of Cell Science</i> , 2006, 119, 4702-4709.	1.2	95
125	Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 105-113.	0.7	50
126	MDR1 Genetic Polymorphisms and Comparison of MDR1 Haplotype Profiles in Korean and Vietnamese Populations. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 531-535.	1.0	36

#	ARTICLE	IF	CITATIONS
127	Genetic Polymorphism of CYP2C9 in a Vietnamese Kinh Population. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 208-210.	1.0	32
128	Analysis of benidipine enantiomers in human plasma by liquid chromatography-mass spectrometry using a macrocyclic antibiotic (Vancomycin) chiral stationary phase column. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 814, 75-81.	1.2	19
129	Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the genetic polymorphism. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 191-201.	2.3	68
130	Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 552-563.	1.1	14
131	In vitro metabolism of a new cardioprotective agent, KR-33028 in the human liver microsomes and cryopreserved human hepatocytes. <i>Archives of Pharmacal Research</i> , 2005, 28, 1287-1292.	2.7	6
132	High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2005, 19, 2651-2658.	0.7	148
133	Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro. <i>Xenobiotica</i> , 2005, 35, 27-38.	0.5	24
134	Diclofenac attenuates Wnt/ β -catenin signaling in colon cancer cells by activation of NF- κ B. <i>FEBS Letters</i> , 2005, 579, 4213-4218.	1.3	55
135	Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 397-402.	1.1	42
136	Simple and Sensitive Assay of Torasemide in Human Plasma by High-Performance Liquid Chromatography Using a Monolithic Silica Column. <i>Chromatographia</i> , 2004, 60, 639-643.	0.7	12
137	Determination of benidipine in human plasma using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 805, 311-314.	1.2	20
138	Simultaneous determination of ebastine and its three metabolites in plasma using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 813, 75-80.	1.2	31
139	Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 157-162.	2.3	82
140	Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 104-112.	2.3	98
141	Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. <i>Xenobiotica</i> , 2004, 34, 429-438.	0.5	18
142	STEREOSELECTIVE METABOLISM OF LANSOPRAZOLE BY HUMAN LIVER CYTOCHROME P450 ENZYMES. <i>Drug Metabolism and Disposition</i> , 2003, 31, 1227-1234.	1.7	64
143	Inhibitory Effects of Tricyclic Antidepressants (TCAs) on Human Cytochrome P450 Enzymes in Vitro: Mechanism of Drug Interaction between TCAs and Phenytoin. <i>Drug Metabolism and Disposition</i> , 2002, 30, 1102-1107.	1.7	67
144	Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 111-119.	5.7	86

#	ARTICLE	IF	CITATIONS
145	Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism. <i>Clinical Pharmacokinetics</i> , 2002, 41, 913-958.	1.6	771
146	Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19*. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 90-99.	2.3	68
147	Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 277-280.	1.1	107
148	Assessment of Efficacy and Safety of Haloxazolam in Psychiatric Patients with Insomnia. <i>Journal of the Korean Society for Clinical Pharmacology and Therapeutics</i> , 1995, 3, 36.	0.1	0
149	Bioequivalence of Generic Nortriptyline Tablet. <i>Journal of the Korean Society for Clinical Pharmacology and Therapeutics</i> , 1993, 1, 3.	0.1	0